ID   BICR 10
AC   CVCL_2307
SY   BICR-10; BICR10; BICR-10 R; Beatson Institute for Cancer Research 10
DR   CLO; CLO_0009941
DR   EFO; EFO_0006540
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 835
DR   BioSample; SAMN03473143
DR   cancercelllines; CVCL_2307
DR   CancerTools; 152841
DR   Cell_Model_Passport; SIDM00077
DR   Cosmic-CLP; 1290724
DR   DepMap; ACH-001331
DR   ECACC; 04072103
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1290724
DR   GEO; GSM827321
DR   GEO; GSM1669621
DR   LINCS_LDP; LCL-1203
DR   PharmacoDB; BICR10_93_2019
DR   Progenetix; CVCL_2307
DR   Wikidata; Q54796517
DR   Ximbio; 152841
RX   PubMed=7646764;
RX   PubMed=8390283;
RX   PubMed=9307265;
RX   PubMed=10523844;
RX   PubMed=20215515;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31321735;
RX   PubMed=32990596;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   HLA typing: A*01:01,01:01; B*14:01,44:02; C*01:02,07:06 (PubMed=26589293).
CC   Karyotypic information: Near diploid karyotype (PubMed=31321735).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.05%; Native American=0%; East Asian, North=0.01%; East Asian, South=0%; South Asian=0.82%; European, North=71.25%; European, South=27.87% (PubMed=30894373).
CC   Derived from site: In situ; Oral cavity, buccal mucosa; UBERON=UBERON_0006956.
ST   Source(s): Cosmic-CLP; ECACC; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12,14
ST   D13S317: 8,14
ST   D16S539: 9,13
ST   D18S51: 14,19
ST   D21S11: 30.2,32.2
ST   D3S1358: 17
ST   D5S818: 11,13
ST   D7S820: 11,12
ST   D8S1179: 13,14
ST   FGA: 21,22
ST   Penta D: 9,12
ST   Penta E: 7,18
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C4040; Buccal mucosa squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 31
//
RX   PubMed=7646764; DOI=10.1002/mc.2940130408;
RA   Edington K.G., Loughran O.P., Berry I.J., Parkinson E.K.;
RT   "Cellular immortality: a late event in the progression of human
RT   squamous cell carcinoma of the head and neck associated with p53
RT   alteration and a high frequency of allele loss.";
RL   Mol. Carcinog. 13:254-265(1995).
//
RX   PubMed=8390283; DOI=10.1038/bjc.1993.238;
RA   Burns J.E., Baird M.C., Clark L.J., Burns P.A., Edington K.G.,
RA   Chapman C., Mitchell R., Robertson G., Soutar D., Parkinson E.K.;
RT   "Gene mutations and increased levels of p53 protein in human squamous
RT   cell carcinomas and their cell lines.";
RL   Br. J. Cancer 67:1274-1284(1993).
//
RX   PubMed=9307265;
RA   McGregor F., Wagner E., Felix D.H., Soutar D., Parkinson E.K.,
RA   Harrison P.R.;
RT   "Inappropriate retinoic acid receptor-beta expression in oral
RT   dysplasias: correlation with acquisition of the immortal phenotype.";
RL   Cancer Res. 57:3886-3889(1997).
//
RX   PubMed=10523844; DOI=10.1038/sj.onc.1202957;
RA   Agochiya M., Brunton V.G., Owens D.W., Parkinson E.K., Paraskeva C.,
RA   Keith W.N., Frame M.C.;
RT   "Increased dosage and amplification of the focal adhesion kinase gene
RT   in human cancer cells.";
RL   Oncogene 18:5646-5653(1999).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31321735; DOI=10.1007/s13258-019-00850-6;
RA   Ribeiro I.P., Rodrigues J.M., Mascarenhas A., Marques V., Caramelo F.,
RA   Juliao M.J., Liehr T., Melo J.B., Carreira I.M.;
RT   "(Cyto)genomic and epigenetic characterization of BICR 10 cell line
RT   and three new established primary human head and neck squamous cell
RT   carcinoma cultures.";
RL   Genes Genomics 41:1207-1221(2019).
//
RX   PubMed=32990596; DOI=10.7554/eLife.57761;
RA   Chai A.W.Y., Yee P.S., Price S., Yee S.M., Lee H.M., Tiong V.K.H.,
RA   Goncalves E., Behan F.M., Bateson J., Gilbert J.G.R., Tan A.-C.,
RA   McDermott U., Garnett M.J., Cheong S.-C.;
RT   "Genome-wide CRISPR screens of oral squamous cell carcinoma reveal
RT   fitness genes in the Hippo pathway.";
RL   eLife 9:e57761.1-e57761.34(2020).
//